LYN and hepatocellular carcinoma: In addition, while Dasatinib treatment was able to effectively inhibit p‐Lyn and p‐Src expression in HCC cells, the antineoplastic activity of Dasatinib was not correlated to c‐Myc, p‐Lyn, or p‐Src levels.